Skip to main content
Cellular and Molecular Life Sciences: CMLS logoLink to Cellular and Molecular Life Sciences: CMLS
. 2006 Mar 29;63(9):1017–1023. doi: 10.1007/s00018-005-5543-z

The clinical potential of sphingolipid-based therapeutics

T E Fox 1, C M Finnegan 2, R Blumenthal 2,, M Kester 1
PMCID: PMC11136019  PMID: 16568241

Abstract.

The era of sphingolipid-based therapeutics is upon us. A large body of work has been accumulating that demonstrates the distinct biological roles of sphingolipids in maintaining a homeostatic environment and in responding to environmental stimuli to regulate cellular processes. It is thus necessary to further investigate alterations in sphingolipid-metabolism in pathological conditions and, in turn, try to exploit altered sphingolipid-me- tabolizing enzymes and their metabolites as therapeutic targets. This review will examine how advances in the fields of drug delivery, drug discovery, synthetic chemistry, enzyme replacement therapy, immunobiology, infectious disease and nanotechnology have delivered the potential and promise of utilizing and/or targeting sphingolipid metabolites as therapies for diverse diseases.

Keywords. Sphingolipids, ceramide, therapeutics, inflammation, infectivity, immunity

Footnotes

Received 11 November 2005; received after revision 19 January 2006; accepted 30 January 2006


Articles from Cellular and Molecular Life Sciences: CMLS are provided here courtesy of Springer

RESOURCES